| scholarly article | Q13442814 |
| P50 | author | Zhi Ping Xu | Q57003255 |
| Li Li | Q42225039 | ||
| P2093 | author name string | Hong Zou | |
| Wenyi Gu | |||
| Michael Monteiro | |||
| Ines Garcia Carcedo | |||
| P2860 | cites work | A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer. | Q51732207 |
| Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. | Q54054994 | ||
| Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers | Q83340245 | ||
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer | Q24338724 | ||
| Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy | Q24628724 | ||
| Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
| Nanoparticles of biodegradable polymers for clinical administration of paclitaxel | Q31047920 | ||
| Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. | Q33273421 | ||
| Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells | Q33423982 | ||
| Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules | Q33775805 | ||
| Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways | Q33934922 | ||
| The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer | Q34038031 | ||
| The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer | Q34086875 | ||
| Treatment of HIV-associated Kaposi's sarcoma with paclitaxel | Q34299276 | ||
| Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. | Q34450398 | ||
| Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules | Q34528991 | ||
| Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma | Q34810176 | ||
| Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist | Q34973092 | ||
| Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. | Q35507680 | ||
| Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. | Q36097117 | ||
| Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel | Q36920871 | ||
| First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel | Q37419857 | ||
| PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress | Q37799638 | ||
| Layered double hydroxide nanoparticles as target-specific delivery carriers: uptake mechanism and toxicity | Q37906629 | ||
| Treatment of metastatic colorectal cancer | Q37910392 | ||
| Polymer nanoparticles--a novel strategy for administration of Paclitaxel in cancer chemotherapy | Q38029750 | ||
| The PI3 kinase signaling pathway in prostate cancer | Q38065198 | ||
| Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer | Q38065200 | ||
| Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma | Q38069238 | ||
| Paclitaxel and gemcitabine combinational drug-loaded mucoadhesive delivery system in the treatment of colon cancers | Q38983439 | ||
| Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary | Q39022471 | ||
| Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform. | Q39062649 | ||
| Preclinical research in treatment of pancreatic cancer | Q39126978 | ||
| Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells. | Q39396274 | ||
| Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway | Q39554627 | ||
| A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis | Q39645455 | ||
| NVP-BEZ235 as a new therapeutic option for sarcomas. | Q39752874 | ||
| Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. | Q39832054 | ||
| A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells | Q39840228 | ||
| Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells | Q39874352 | ||
| Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations | Q40081472 | ||
| Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways | Q40302272 | ||
| Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). | Q40738921 | ||
| Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. | Q40933283 | ||
| Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation | Q42504535 | ||
| Curcumin Enhances Oral Bioavailability and Anti-Tumor Therapeutic Efficacy of Paclitaxel upon Administration in Nanoemulsion Formulation | Q42906039 | ||
| Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. | Q42984399 | ||
| Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines | Q43411752 | ||
| Potential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancer | Q43460220 | ||
| PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. | Q46544691 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| cell growth | Q189159 | ||
| paclitaxel | Q423762 | ||
| colon cancer | Q18555025 | ||
| P304 | page(s) | 1947-1958 | |
| P577 | publication date | 2016-05-05 | |
| P1433 | published in | International Journal of Nanomedicine | Q6051502 |
| P1476 | title | Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis | |
| P478 | volume | 11 |
| Q91705498 | Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment |
| Q46366459 | Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers |
| Q93155378 | Dual role of Endoplasmic Reticulum Stress-Mediated Unfolded Protein Response Signaling Pathway in Carcinogenesis |
| Q37720022 | Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation |
| Q47105720 | Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. |
| Q54112259 | Metformin Protects Against Spinal Cord Injury by Regulating Autophagy via the mTOR Signaling Pathway. |
| Q55709275 | Optimization of Formulations Consisting of Layered Double Hydroxide Nanoparticles and Small Interfering RNA for Efficient Knockdown of the Target Gene. |
| Q90050680 | PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition |
| Q53698561 | Paclitaxel increases the sensitivity of lung cancer cells to lobaplatin via PI3K/Akt pathway. |
| Q54107698 | Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma. |
| Q91713110 | Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells |
| Q98513603 | TMPRSS13 promotes cell survival, invasion, and resistance to drug-induced apoptosis in colorectal cancer |
| Q42360077 | Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer |
| Q52560224 | Targeting of epigenetic regulators in neuroblastoma. |
| Q91716178 | Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer |
| Q54121252 | Wogonoside inhibits cell growth and induces mitochondrial-mediated autophagy-related apoptosis in human colon cancer cells through the PI3K/AKT/mTOR/p70S6K signaling pathway. |
Search more.